FDA approves oral GLP-1 orforglipron for weight management
The clearance gives Eli Lilly an oral small-molecule incretin option alongside injectable GLP-1 receptor agonists already on the market.
DO
By Daniel Okafor · Regulatory Correspondent
Apr 1 03:00 ETSource: Medscape
The wire
- 01Medscape reports the FDA has approved orforglipron for weight management.
- 02An approved daily oral incretin changes the supply, storage and counseling picture for prescribers and pharmacists used to injectable GLP-1 therapy.
- 03Labeling details, pricing and payer coverage terms will determine how quickly the drug displaces injectable options in practice.
From the source
Read at medscape.comFDA Okays Orforglipron for Weight Management
